SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

Form 8-A

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

 

Xenetic Biosciences, Inc

(Exact name of registrant as specified in its charter)

 

NV 45-2952962
(State of incorporation or organization) (I.R.S. Employer Identification No.)
   
99 Hayden Avenue  
Suite 230, Lexington, MA 02421
 (Address of principal executive offices) (Zip Code)
   
Securities to be registered pursuant to Section 12(b) of the Act:
   

Title of each class

to be so registered

Name of each exchange of which

each class is to be registered

Common stock, par value of $0.001

 

NASDAQ Capital Market

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. [X]

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. [  ]

 

Securities Act registration statement file number to which this form relates: 333-211249 and 333-178082 (if applicable)

 

Securities to be registered pursuant to Section 12(g) of the Act:

 

None

(Title of class)

 

 

 
 
 

 

Item 1. Description of Registrant’s Securities to be Registered.

 

The description of securities contained in Registrant’s Registration Statement on Form S-1, as amended, filed with the commission (File No. 333-211249) is incorporated by reference into this registration statement.

 

Item 2. Exhibits

 

Under the “Instructions as to Exhibits” with respect to Form 8-A, no exhibits are required to be filed with this registration statement because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities to be registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

 

 

SIGNATURE

 

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

DATE: November 1, 2016

 

Xenetic Biosciences, Inc.

 

 

By:    /s/ M. Scott Maguire               

M. Scott Maguire

Title: Chief Executive Officer